Jason Aryeh, serving as a director at Ligand Pharmaceuticals Inc (NASDAQ:LGND), has completed a significant divestment of company equity. According to a recent Securities and Exchange Commission (SEC) filing, Aryeh sold a combined total of 5,000 shares of the firm's common stock. The transaction yielded proceeds of approximately $1,250,000, executed at a uniform price of $250.0 per share. This sale activity unfolds against a backdrop where LGND stock is trading in close proximity to its 52-week peak of $258.56. The equity has demonstrated substantial momentum, delivering a 122% return over the trailing twelve-month period. Despite this price appreciation, current valuation metrics suggest the stock may be trading above its intrinsic fair value.
The execution of the sale was split across two consecutive trading days. On June 10, 2026, Aryeh offloaded 500 shares. The following day, June 11, 2026, the director proceeded to sell an additional 4,500 shares. These transactions represent a notable reduction in direct equity exposure for the executive.
Concurrently with the sales, Aryeh accumulated new equity compensation from the company. On June 5, 2026, he was awarded 836 restricted stock units (RSUs). Each RSU confers a contingent right to receive one share of Ligand's common stock. The vesting schedule for these units is tied to the earlier of the next annual meeting of stockholders or the first anniversary of the grant date. On that same date, Aryeh also received a grant of 2,938 non-qualified stock options. These options carry an exercise price of $237.0 per share and maintain an expiration date of June 5, 2036. Similar to the RSUs, the stock options are scheduled to vest upon the earlier of the next annual stockholder meeting or the one-year anniversary of the grant.
Following the completion of these transactions, Aryeh's direct ownership position in Ligand Pharmaceuticals stands at 102,580 shares of common stock. This figure reflects a reallocation of 7,825 shares within his account records. Beyond direct holdings, Aryeh maintains an indirect stake of 13,000 shares. These indirect shares are held through specific funds managed by JALAA Equities, LP, JLV Investments, LP, and their respective affiliates. As the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP, Aryeh may be classified as a beneficial owner of these securities.
Corporate performance metrics for Ligand Pharmaceuticals have recently drawn scrutiny. The company reported first quarter 2026 earnings that failed to align with analyst projections. The adjusted earnings per share (EPS) was recorded at $1.63, marking an 11.41% negative surprise relative to the forecasted $1.84. Revenue performance also missed targets, with actual figures coming in at $51.72 million against an anticipated $59.07 million. This revenue discrepancy represents a 12.44% shortfall. These results have prompted increased attention from the investment community regarding the company's operational execution.
Strategic restructuring activities are also underway. Ligand Pharmaceuticals has amended its existing merger agreement with XOMA Royalty Corporation. The revised agreement formally includes XOMA Royalty Holdings Corporation as a party. Under the updated terms, Flex Merger Sub, Inc., a wholly owned subsidiary of Ligand, will merge with XOMA Royalty Holdings Corporation. Upon completion, the combined entity will operate as a wholly owned subsidiary of Ligand. These structural changes and recent financial results are expected to influence investor sentiment and strategic decision-making processes within the biopharmaceutical sector.